Until very recently, no serious consequences had been dealt out by India's Central Drugs Standard Control Organization (CDSCO), even for Ranbaxy Laboratories, which last year pled guilty to criminal charges in the U.S. for selling subpar drugs. But CDSCO appears to be turning over a new leaf--at least a little.
Apple has discussed collaboration with several promiminent healthcare players as it prepares to roll out its HealthKit service, which is anticipated to be an element of the iPhone 6 that's planned for this fall. The players include Mount Sinai Hospital, the Cleveland Clinic, Johns Hopkins and electronic health records company Allscripts, according to Reuters.
Philadelphia's Tarsa Therapeutics has nailed down a $10 million credit facility to help bankroll an FDA submission for Ostora, the company's treatment for postmenopausal osteoporosis.
Expectations are high for the recently FDA-approved, donated lung preservation device, XVIVO Perfusion System with STEEN Solution.
Abbott secured Medicare coverage for its MitraClip System to reduce the backward flow of blood through the heart's mitral valve (mitral regurgitation), the company announced Aug. 12. Earlier this month the federal Centers for Medicare and Medicaid services also approved the device for additional reimbursement in the form of new technology add-on payments due to its innovative nature.
Exact Sciences won FDA approval for its stool-based colorectal cancer diagnostic, charting a regulatory milestone and picking up proposed national coverage for its product along the way.
South Korea's Celltrion is aiming to be second in line when biosimilars make their U.S. landfall, filing an FDA application to market a knockoff of Johnson & Johnson's blockbuster Remicade.
The U.K.'s National Institute for Health and Care Excellence wants to know what "societal values" should be considered, along with cost and efficiency, when making decisions. Now an appointed group of 30 people have given it that feedback, PMLive reports.
Exact Sciences gained FDA premarket approval for its new, cutting-edge colorectal cancer screening test. It is also well ahead in the insurance reimbursement battle.
With FDA bans in place on two plants, India's Wockhardt saw its profits slip in the first part of this year. But with access to its largest market still severely curtailed, Wockhardt has been unable to get its financial footing and profits went crashing in its last quarter, off 94%.